Votrient Combination Therapy Still An Option In Pediatrics, Subcommittee Tells GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
The company reported difficulties combining the drug with other chemotherapies in adults, but FDA's pediatric oncology subcommittee says that may not be the case in children.
You may also be interested in...
Study Design, Feasibility Issues Going To Pediatric Oncology Advisory Subcommittee
Four products to be considered at Nov. 1 meeting, including whether one therapy can advance a cure rate that hasn't changed in 20 years.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.